CytoSorbents Announces Proposed Offering of Common Stock

CytoSorbents Announces Proposed Offering

MONMOUTH JUNCTION, NJ, March 30, 2017

- CytoSorbents Corporation (NASDAQ: CTSO),

a critical care immunotherapy leader commercializing its flagship CytoSorb blood

filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has

commenced an underwritten public offering of its common stock. The company expects to grant the underwriters a 30-day option to

purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the

shares in the offering will be sold by CytoSorbents. This offering is subject to market conditions and there can be no assurance

as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The company intends to

use the net proceeds from this offering for general corporate and working capital purposes, including advancing its U.S. pivotal

trial for treatment of inflammation in conjunction with cardiac surgery.

Cowen and Company is acting as the sole

book-running manager and representative of the underwriters for the offering.

A shelf registration statement related

to the offering was filed with the Securities and Exchange Commission (SEC) on July 23, 2015 and declared effective by the SEC

The offering is being made only by means

of a written prospectus and prospectus supplement. A preliminary prospectus supplement related to the offering has been filed with

the SEC and is available at the SEC's website located at www.sec.gov. A copy of the preliminary prospectus supplement and related

prospectus relating to these securities may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial

Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by calling 631-274-2806, or by faxing 631-254-7140.

This press release shall not constitute

an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction

in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of

any such state or jurisdiction.

About CytoSorbents Corporation (NASDAQ:

Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb

is approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal

cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise

cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury

and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective

treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators, such as

cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents

has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated

the safety of intra-operative CytoSorb use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans

to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb has been used safely in more than 20,000

human treatments to date. A companion product, VetResQ , based on similar underlying technology to CytoSorb, is now commercially

available in the United States for the treatment of hyper-inflammatory conditions in animal health.

CytoSorbents' purification technologies

are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids

by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess

of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes

of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), and others. The Company

has numerous products under development based upon this unique blood purification technology including CytoSorb-XL, HemoDefend ,

VetResQ , ContrastSorb, DrugSorb, and others. As of March 28, 2017, we owned 32 issued U.S. patents and had multiple pending

patent applications worldwide. Our patent portfolio includes 16 issued U.S. patents as well as multiple pending patent applications

directed to various compositions and methods of use related to our blood purification technologies, which are expected to expire

between 2018 and 2026, absent any patent term extensions.

Forward-Looking Statements

This press release includes forward-looking

statements, including with respect to the anticipated closing of the offering described herein and the use of net proceeds therefrom,

intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These

forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions

and are not historical facts and typically are identified by use of terms such as "may," "should," "could,"

"expect," "plan," "anticipate," "believe," "estimate," "predict," "potential,"

"continue" and similar words, although some forward-looking statements are expressed differently. You should be aware

that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual

results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause

or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed

with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases

and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks

and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements.

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,

future events, or otherwise, other than as required under the Federal securities laws.

Cytosorbents Contact:

Public Relations Contact: